Neoadjuvant chemotherapy followed by robotic radical hysterectomy in locally advanced cervical cancer: A multi-institution study

Enrico Vizza, Giacomo Corrado, Vanna Zanagnolo, Tiziana Tomaselli, Giuseppe Cutillo, Emanuela Mancini, Angelo Maggioni

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective Minimally invasive surgery has been performed in locally advanced cervical cancer (LACC) without adverse effect in patient's overall prognosis and survival. The aim of this report is to evaluate the feasibility and morbidity of total robotic radical hysterectomy (TRRH) with pelvic lymphadenectomy in patients with LACC after neo-adjuvant chemotherapy (NACT). Methods From February 2008 to April 2013 a retrospective data collection of women undergoing TRRH for cervical cancer stage FIGO IB2 to IIB, after neo-adjuvant chemotherapy, was conducted at "Regina Elena" National Cancer Institute of Rome and European Institute of Oncology of Milan. All patients deemed operable underwent TRRH with pelvic lymphadenectomy within 4 weeks from the last chemotherapy cycle. Results Median operative time was 225 min (range, 105-387 min). The median blood loss was 150 mL (range, 30-700 mL). The median number of removed pelvic lymph nodes was 23 (range, 8-69). Sixteen patients had an optimal response (12 PCR, 4 pPR1) to chemotherapy, 33 patients had a pPR2 and 11 patient showed stable disease. Adjuvant therapy was administrated in 36 patients (60%). We experienced one intra-operative complication and 19 post-operative complications, but no conversions to laparotomy were necessary to manage these complications. Six patients received a blood transfusion. At the time of this report, with a median follow-up of 28.9 months, 50 patients (83%) are free from recurrence. Conclusion This experience demonstrates the feasibility of TRRH pelvic lymphadenectomy after NACT in LACC with good accuracy and safety.

Original languageEnglish
Pages (from-to)180-185
Number of pages6
JournalGynecologic Oncology
Volume133
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Robotics
Hysterectomy
Uterine Cervical Neoplasms
Drug Therapy
Adjuvant Chemotherapy
Lymph Node Excision
Minimally Invasive Surgical Procedures
National Cancer Institute (U.S.)
Operative Time
Blood Transfusion
Laparotomy
Lymph Nodes
Morbidity
Safety
Recurrence
Polymerase Chain Reaction
Survival

Keywords

  • Locally advanced cervical cancer
  • Minimally invasive surgery
  • Neo-adjuvant chemotherapy
  • Robotic radical hysterectomy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Neoadjuvant chemotherapy followed by robotic radical hysterectomy in locally advanced cervical cancer : A multi-institution study. / Vizza, Enrico; Corrado, Giacomo; Zanagnolo, Vanna; Tomaselli, Tiziana; Cutillo, Giuseppe; Mancini, Emanuela; Maggioni, Angelo.

In: Gynecologic Oncology, Vol. 133, No. 2, 2014, p. 180-185.

Research output: Contribution to journalArticle

@article{f5ffe605be6c4d80941aa9f3a48fffe6,
title = "Neoadjuvant chemotherapy followed by robotic radical hysterectomy in locally advanced cervical cancer: A multi-institution study",
abstract = "Objective Minimally invasive surgery has been performed in locally advanced cervical cancer (LACC) without adverse effect in patient's overall prognosis and survival. The aim of this report is to evaluate the feasibility and morbidity of total robotic radical hysterectomy (TRRH) with pelvic lymphadenectomy in patients with LACC after neo-adjuvant chemotherapy (NACT). Methods From February 2008 to April 2013 a retrospective data collection of women undergoing TRRH for cervical cancer stage FIGO IB2 to IIB, after neo-adjuvant chemotherapy, was conducted at {"}Regina Elena{"} National Cancer Institute of Rome and European Institute of Oncology of Milan. All patients deemed operable underwent TRRH with pelvic lymphadenectomy within 4 weeks from the last chemotherapy cycle. Results Median operative time was 225 min (range, 105-387 min). The median blood loss was 150 mL (range, 30-700 mL). The median number of removed pelvic lymph nodes was 23 (range, 8-69). Sixteen patients had an optimal response (12 PCR, 4 pPR1) to chemotherapy, 33 patients had a pPR2 and 11 patient showed stable disease. Adjuvant therapy was administrated in 36 patients (60{\%}). We experienced one intra-operative complication and 19 post-operative complications, but no conversions to laparotomy were necessary to manage these complications. Six patients received a blood transfusion. At the time of this report, with a median follow-up of 28.9 months, 50 patients (83{\%}) are free from recurrence. Conclusion This experience demonstrates the feasibility of TRRH pelvic lymphadenectomy after NACT in LACC with good accuracy and safety.",
keywords = "Locally advanced cervical cancer, Minimally invasive surgery, Neo-adjuvant chemotherapy, Robotic radical hysterectomy",
author = "Enrico Vizza and Giacomo Corrado and Vanna Zanagnolo and Tiziana Tomaselli and Giuseppe Cutillo and Emanuela Mancini and Angelo Maggioni",
year = "2014",
doi = "10.1016/j.ygyno.2014.02.035",
language = "English",
volume = "133",
pages = "180--185",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy followed by robotic radical hysterectomy in locally advanced cervical cancer

T2 - A multi-institution study

AU - Vizza, Enrico

AU - Corrado, Giacomo

AU - Zanagnolo, Vanna

AU - Tomaselli, Tiziana

AU - Cutillo, Giuseppe

AU - Mancini, Emanuela

AU - Maggioni, Angelo

PY - 2014

Y1 - 2014

N2 - Objective Minimally invasive surgery has been performed in locally advanced cervical cancer (LACC) without adverse effect in patient's overall prognosis and survival. The aim of this report is to evaluate the feasibility and morbidity of total robotic radical hysterectomy (TRRH) with pelvic lymphadenectomy in patients with LACC after neo-adjuvant chemotherapy (NACT). Methods From February 2008 to April 2013 a retrospective data collection of women undergoing TRRH for cervical cancer stage FIGO IB2 to IIB, after neo-adjuvant chemotherapy, was conducted at "Regina Elena" National Cancer Institute of Rome and European Institute of Oncology of Milan. All patients deemed operable underwent TRRH with pelvic lymphadenectomy within 4 weeks from the last chemotherapy cycle. Results Median operative time was 225 min (range, 105-387 min). The median blood loss was 150 mL (range, 30-700 mL). The median number of removed pelvic lymph nodes was 23 (range, 8-69). Sixteen patients had an optimal response (12 PCR, 4 pPR1) to chemotherapy, 33 patients had a pPR2 and 11 patient showed stable disease. Adjuvant therapy was administrated in 36 patients (60%). We experienced one intra-operative complication and 19 post-operative complications, but no conversions to laparotomy were necessary to manage these complications. Six patients received a blood transfusion. At the time of this report, with a median follow-up of 28.9 months, 50 patients (83%) are free from recurrence. Conclusion This experience demonstrates the feasibility of TRRH pelvic lymphadenectomy after NACT in LACC with good accuracy and safety.

AB - Objective Minimally invasive surgery has been performed in locally advanced cervical cancer (LACC) without adverse effect in patient's overall prognosis and survival. The aim of this report is to evaluate the feasibility and morbidity of total robotic radical hysterectomy (TRRH) with pelvic lymphadenectomy in patients with LACC after neo-adjuvant chemotherapy (NACT). Methods From February 2008 to April 2013 a retrospective data collection of women undergoing TRRH for cervical cancer stage FIGO IB2 to IIB, after neo-adjuvant chemotherapy, was conducted at "Regina Elena" National Cancer Institute of Rome and European Institute of Oncology of Milan. All patients deemed operable underwent TRRH with pelvic lymphadenectomy within 4 weeks from the last chemotherapy cycle. Results Median operative time was 225 min (range, 105-387 min). The median blood loss was 150 mL (range, 30-700 mL). The median number of removed pelvic lymph nodes was 23 (range, 8-69). Sixteen patients had an optimal response (12 PCR, 4 pPR1) to chemotherapy, 33 patients had a pPR2 and 11 patient showed stable disease. Adjuvant therapy was administrated in 36 patients (60%). We experienced one intra-operative complication and 19 post-operative complications, but no conversions to laparotomy were necessary to manage these complications. Six patients received a blood transfusion. At the time of this report, with a median follow-up of 28.9 months, 50 patients (83%) are free from recurrence. Conclusion This experience demonstrates the feasibility of TRRH pelvic lymphadenectomy after NACT in LACC with good accuracy and safety.

KW - Locally advanced cervical cancer

KW - Minimally invasive surgery

KW - Neo-adjuvant chemotherapy

KW - Robotic radical hysterectomy

UR - http://www.scopus.com/inward/record.url?scp=84899649532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899649532&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2014.02.035

DO - 10.1016/j.ygyno.2014.02.035

M3 - Article

C2 - 24589412

AN - SCOPUS:84899649532

VL - 133

SP - 180

EP - 185

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -